We intend to continue our business development effort by adding other proven domestic and international biotechnology partners to monetize the China health care market
scroll
Dec 5, 2020
ASH 2020, United States
An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma